humanitarian
Archived signal
Human medicines European public assessment report (EPAR): Pebrilzo, pertuzumab, Status: Opinion
Human medicines European public assessment report (EPAR): Zumrad, sasanlimab, Status: Application withdrawn
Reported by EMA What Is New
Read the complete report at EMA What Is New ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
12 reports · 2 sources
EMA What Is NewHuman medicines European public assessment report (EPAR): Pebrilzo, pertuzumab, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Frehemgo, denecimig, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Sepalna, senaparib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Inijaq, tofacitinib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Ruxolitinib Zentiva, ruxolitinib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Lifyorli, relacorilant, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Zeydovio, glepaglutide, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Sepalna, senaparib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Ruxolitinib Zentiva, ruxolitinib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: Opinion2 recorded states
Signal first indexedP2 · 99% quality · 2 sources
Headline updatedP2 · 99% quality · 2 sources